Insider transactions

James Healy

CIK 1245624 · last filed 2026-06-12

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$755.41M
Companies
21
Total Filings
151
Lifetime Open-Market Net
$113.76M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

MRNS price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
3000 SAND HILL ROAD, 4-250
MENLO PARK, CA 94025
Related Filers
Michael Powell — 57 joint filings, latest 2021-05-18
Eric Buatois — 28 joint filings, latest 2016-10-24
Anand Mehra — 26 joint filings, latest 2019-11-19
INTERMUNE INC — 21 joint filings, latest 2014-10-02
SOFINNOVA VENTURE PARTNERS VII L P — 21 joint filings, latest 2014-07-11
Sofinnova Management VII, L.L.C. — 21 joint filings, latest 2014-07-11
Sofinnova Management VIII, L.L.C. — 13 joint filings, latest 2018-09-20
Sofinnova Management IX, L.L.C. — 12 joint filings, latest 2020-08-12
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BIOA Director 2,227,124 $5.12 $11.40M $12.00M 3 2026-06-12
RAPP Director 39,661 $26.76 $1.06M $10.58M 4 2026-06-10
SPTX Director 2,731,538 $21.55 $58.86M $0 1 2026-05-04
Y-mAbs Therapeutics, Inc. (YMAB) Delisted Director 2,250,961 $8.61 $19.38M $10.52M 10 2025-07-02
NTRA Director 1,596,540 $409.05 $653.06M -$22.23M 33 2025-04-29
BOLT Director 115,222 $6.40 $737.4K $9.00M 5 2024-06-14
Karuna Therapeutics, Inc. (KRTX) Delisted Director 0 $329.83 $0 $44.62M 16 2024-03-18
AVBP Director 1,252,308 $15.09 $18.90M $8.00M 1 2024-01-31
CinCor Pharma, Inc. (CINC) Delisted Director 6,103,360 $29.06 $177.36M $20.38M 3 2022-08-15
CHRS Director 70,086 $1.05 $73.9K -$22.15M 19 2022-02-11
Iterum Therapeutics plc (ITRM) Delisted Director 115,511 $0.03 $3.5K $6.50M 5 2020-01-23
Entasis Therapeutics Holdings Inc. (ETTX) Delisted 10%+ Owner 842,454 $2.19 $1.84M $25.33M 1 2018-10-02
EDGE Director 142,636 $52.10 $7.43M $8.90M 4 2017-06-21
AMRN Director 320,579 $12.09 $3.88M -$47.71M 13 2016-07-13
HYPERION THERAPEUTICS INC (HPTX) Delisted Director 0 — — -$3.55M 3 2015-05-08
ALIMERA SCIENCES INC (ALIM) Delisted 10%+ Owner 169,753 $5.54 $940.4K $0 1 2014-09-15
MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted 10%+ Owner 7,000 $0.55 $3.9K $54.05M 1 2014-08-07
Anthera Pharmaceuticals Inc (ANTH) Delisted Director 10,719 — — -$474.0K 8 2013-05-20
HUMANIGEN, INC (KBIO) Delisted Director 3,173 — — $0 2 2013-05-02
Paratek Pharmaceuticals, Inc. (NOVC) Delisted Director 2,178,437 — — $0 3 2008-03-31
COTHERIX INC (CTRX) Delisted Director 0 — — $0 2 2007-01-10

Recent Filings · Page 8 of 16

151 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-01-14 NTRA Exer (M) +22,338 $248.1K EDGAR
2020-01-13 CHRS Exer (M) +69,994 $498.4K EDGAR
2019-11-27 NTRA Exer (M) +7,278 $0 EDGAR
2019-11-25 Karuna Therapeutics, Inc. (KRTX) Delisted Buy (P) +156,250 $15.00M EDGAR
2019-11-01 Y-mAbs Therapeutics, Inc. (YMAB) Delisted Buy (P) +90,000 $2.52M EDGAR
2019-07-02 CHRS Sell (S) −360,000 -$8.03M EDGAR
2019-07-02 Karuna Therapeutics, Inc. (KRTX) Delisted Mixed +1,729,352 $11.20M EDGAR
2019-07-01 Karuna Therapeutics, Inc. (KRTX) Delisted Grant (A) — $0 EDGAR
2019-06-24 CHRS Sell (S) −317,130 -$6.78M EDGAR
2019-06-17 Iterum Therapeutics plc (ITRM) Delisted Grant (A) — $0 EDGAR
Showing 71–80 of 151
Page 8 of 16
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.